Insmed Inc at JPMorgan Healthcare Conference Transcript
My name is Jess Fye. I am a senior biotech analyst at JPMorgan, and we are continuing the 42nd Annual Healthcare Conference today with Insmed. I'm joined by the company's CEO, Will Lewis, who is going to give a presentation. And after that, we're going to move into a Q&A session. If you're in the room, you can raise your hand and we'll give you a mic or you can always use the portal to send questions to me on that iPad over there. But without any further ado, let me pass it over to Will.
Thank you, Jess. It is a pleasure to be here today at what is undoubtedly a very exciting moment in Insmed's history. I'm going to be making some forward-looking statements today. Please review the notice on slide 2 and our public filings for more information.
On slide 3, we have framed out that this is the year of Insmed's transformation. I want to open by saying that what I'm about to communicate to you is going to sound incredibly
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
